Novartis bags first-line approval for Zykadia
June 30, 2017
Source: pharmatimes
503
The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
The drug was originally cleared in the region in 2015 to treat patients with ALK+ metaqstatic non-small cell lung cancer who have progressed on or are intolerant to Pfizer's Xalkori (crizotinib).
Its wider approval comes on the back of data from the Phase III ASCEND-4 trial, which showed a 45 percent reduction in the risk of disease progression patients taking Zykadia verus those taking chemotherapy.
Those treated with first-line Zykadia had a median progression-free survival (PFS) of 16.6 months compared to 8.1 months for patients treated with standard first-line pemetrexed-platinum chemotherapy with pemetrexed maintenance.
The drug also showed a benefit in patients with brain metastases with a median PFS of 10.7 months compared to 6.7 months in the chemotherapy arm.
Around 3-7 percent of all patients with NSCLC have an ALK gene rearrangement.
By Lynn
Copyright©2024 Ddu. All rights reserved.
Read more on
- CRUK researchers develop new early-stage rectal cancer treatment December 12, 2020
- Drugdu.com’s 4 most Popular Veterinary APIs and Veterinary medicine Suppliers September 6, 2018
- 4 Pharmaceutical Machinery Packaging and Materials Suppliers September 6, 2018
- 3 ENT Equipment and Medical Anaesthesia Equipment Suppliers September 6, 2018
- Need Natural Plant Extracts? Here are 4 Suppliers! September 6, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
